Hormonal
Treatment with trans-10,cis-12 conjugated linoleic acid (CLA) reduces triglyceride accumulation in human preadipocytes by decreasing insulin-stimulated glucose uptake, glucose oxidation, and oleic acid uptake/oxidation, while downregulating PPARγ expression and target genes.
This research indicates that a specific form of CLA (trans-10,cis-12) can reduce fat storage in human fat cells by slowing down how they process sugars and fats. However, this was done in a lab dish, not in people. Do not expect this to cause weight loss on its own. It suggests that not all CLA supplements are created equal, and some may even work against fat loss goals by reducing metabolic activity in fat cells.
trans-10,cis-12 CLA decreased insulin-stimulated glucose uptake and oxidation, and reduced insulin-dependent glucose transporter 4 gene expression... trans-10,cis-12 CLA reduced oleic acid uptake and oxidation... trans-10,cis-12 CLA decreased, whereas cis-9,trans-11 CLA increased, the expression of peroxisome proliferator-activated receptor gamma (PPARgamma)... Collectively, trans-10,cis-12 CLA decreased glucose and lipid uptake and oxidation and preadipocyte differentiation by altering preadipocyte gene transcription in a manner that appeared to be due, in part, to decreased PPARgamma expression.
Why this rating
In vitro study on primary human cells; high relevance to human biology but lacks in vivo clinical confirmation of fat loss.
Source
Isomer-specific regulation of metabolism and PPARγ signaling by CLA in human preadipocytes
J. Mark Brown et al. · Journal of Lipid Research · 2003
DOI 10.1194/jlr.m300001-jlr200
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →